This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: F25.9 (Schizoaffective disorder, unspecified) | Special Copayment Reduction: V161 (severe intractable disease, reduced copayment for 5 years after registration) |
| B. Synonyms | Schizoaffective disorder unspecified, schizoaffective psychosis NOS (Not Otherwise Specified), schizoaffective disorder NOS |
| C. Adult onset | Possibility of first onset in adulthood: high — because information is insufficient or the subtype is undetermined, the age-at-onset range varies, but reflecting the characteristics of schizoaffective disorder in general, early adulthood (ages 15–30) is presumed to be the most common time of onset. |
| 1. History | Set as an unspecified code used in ICD-10 when the subtype cannot be determined; mainly used at initial clinical evaluation, in situations of limited information, and in emergencies; recoding is recommended once an accurate subtype diagnosis is established. |
| 2. Causes | Same as the multifactorial etiology of schizoaffective disorder in general; difficult to identify specific causal elements due to insufficient information; thorough exclusion of organic causes during the diagnostic process. |
| 3. Genetics | Shares the same genetic spectrum as F25.0–F25.2; because the subtype is undetermined, association with a specific genetic subtype can be assessed after the diagnosis is established; taking family history is important. |
| 4. General epidemiology | As an administrative code, F25.9 is used frequently in actual clinical settings, but mainly as a provisional diagnostic code rather than a final diagnostic code; relatively commonly observed in health insurance claims data. |
| 5. Pathophysiology | Same as the neurobiological mechanisms of schizoaffective disorder in general; specific mechanisms cannot be identified because the subtype is undetermined; when the subtype is established during follow-up, the corresponding mechanisms apply. |
| 6. Symptoms | Coexistence of schizophrenia symptoms and mood episodes is clinically confirmed, but the subtype cannot be determined without sufficient information; record the main symptom types and severity in as much detail as possible; suicide risk assessment is essential. |
| 7. Signs | Mixture of schizophrenia and mood disorder signs; a plan for longitudinal reassessment to determine the accurate subtype should be established from the beginning; exclusion of organic signs is important. |
| 8. Screening | Thoroughly perform the same tests to exclude organic causes as for F25.0–F25.2; include interviews with family and caregivers to collect sufficient history; establish a plan for collecting additional information to determine the subtype. |
| 9. Diagnosis | A provisional code used when classification into F25.0–F25.2 is not possible because of insufficient clinical information; mainly applied in emergencies, at first visits, and when data referred from outside institutions are insufficient; the goal is subtype reclassification after follow-up. |
| 10. Treatment | Start symptom-based treatment immediately even when the subtype is undetermined; antipsychotics when positive symptoms predominate, add a mood stabilizer when mood episodes accompany; switch to the corresponding treatment protocol once the subtype is established. |
| 11. Prognosis | Prognosis is difficult to predict while the subtype is undetermined, but follows the prognostic characteristics of schizoaffective disorder in general; apply the prognostic characteristics of the corresponding subtype once it is established; establishing an early diagnosis is key to improving prognosis. |
| 12. Prevention | Apply the prevention principles of schizoaffective disorder in general; switch to subtype-specific prevention plans after the subtype is established early; establish relapse prevention maintenance therapy and a suicide prevention safety plan. |
| 13. References | Malaspina D, et al. Schizoaffective disorder in the DSM-5. Schizophr Res. 2013 … and 9 other papers |
Schizoaffective disorder, unspecified (F25.9) is an 'unspecified' code used in the ICD-10 classification system when coexistence of schizophrenia symptoms and mood episodes is clinically confirmed but, owing to the absence of sufficient clinical information, the case cannot be classified into any subtype among F25.0 (manic type), F25.1 (depressive type), F25.2 (mixed type), and F25.8 (other). This code is also called NOS (Not Otherwise Specified), and 'schizoaffective psychosis NOS' is used as a Korean synonym.
The conceptual history of unspecified codes stems from a pragmatic approach in psychiatric classification systems that acknowledges clinical uncertainty. As the DSM and ICD systems developed, increasingly specific diagnostic criteria were presented, but in clinical reality there have always been cases that do not fully meet these criteria or lack sufficient information. In response, an NOS or unspecified code was established in every major diagnostic category.
The F25.9 code is mainly used in the following clinical situations. First, in emergency situations, it is used as a provisional diagnosis when a patient with acute psychotic mood symptoms is brought in before sufficient history taking has been done. Second, in first-visit situations, it is used when the patient is not cooperative or history cannot be obtained from family or caregivers. Third, in situations of insufficient referral data, it is used when the previous records of a patient transferred from an outside institution are insufficient.
Unlike ICD-10, in DSM-5 the 'unspecified' category is separated from schizoaffective disorder, and 'Unspecified Schizophrenia Spectrum and Other Psychotic Disorder' is used as the code corresponding to F25.9.
In clinical practice, F25.9 is observed at a relatively high frequency in health insurance claims data, reflecting that in actual practice it is often difficult to determine the subtype or information is insufficient. However, F25.9 should be used as a provisional code, not a final diagnostic code, and reclassification to a typical subtype after sufficient follow-up and information gathering is recommended. Long-term retention of the diagnostic code can make treatment planning and prognosis prediction difficult.
In Korean clinical practice, use of the F25.9 code remains valid when applying Special Copayment Reduction V161, and the usual clinical flow is to apply F25.9 at initial diagnosis and then recode to a typical subtype through follow-up. Accurate subtype classification is important for determining the direction of treatment (whether to add an antidepressant, choice of mood stabilizer, etc.), prognostic counseling, and establishing a relapse prevention plan.
The cause of schizoaffective disorder, unspecified (F25.9), is understood to share the multifactorial etiology applicable to schizoaffective disorder in general, since the subtype has not been determined. A complex interaction of genetic predisposition, neurodevelopmental abnormalities, neurotransmitter imbalance, and environmental stress factors forms the basis.
Shared multifactorial etiology: Cases classified as F25.9 are also presumed ultimately to share the genetic and neurobiological characteristics of the schizophrenia spectrum and the mood disorder spectrum. Even when the subtype is undetermined, the same holds that abnormalities of the dopamine, serotonin, and glutamate systems underlie the symptoms.
Importance of excluding organic causes: The most important clinical task in the diagnosis of F25.9 is to sufficiently exclude organic causes that induce psychotic symptoms and mood episodes. Thyroid dysfunction, autoimmune encephalitis, brain tumor, temporal lobe epilepsy, substance-induced states, and drug-induced psychosis such as with steroids can show clinical pictures similar to F25.9, and using the F25.9 code without excluding them can lead to treatment errors.
Causal role of substance abuse: Especially in emergency and first-visit situations where the F25.9 code is frequently used, differentiating psychotic mood symptoms due to use of substances such as cannabis, cocaine, methamphetamine, and synthetic cannabinoids from schizoaffective disorder is one of the most important clinical tasks. If symptoms remit completely within 4–6 weeks after stopping the substance, the case should be reclassified as a substance-induced disorder.
Stress-vulnerability model: The stress-vulnerability model, which applies to schizoaffective disorder in general, also applies to F25.9 cases. Clinical expression is understood to occur when psychosocial stress is added to an individual's genetic and neurodevelopmental vulnerability.
The genetics of schizoaffective disorder, unspecified (F25.9), is understood to share the genetic background of schizoaffective disorder in general, since the subtype has not been determined. The genes involved in the same schizophrenia–mood disorder genetic spectrum as F25.0–F25.2 are presumed to act as genetic risk elements in these cases as well.
Shared genetic background of schizoaffective disorder in general: Candidate genes such as CACNA1C, ANK3, DISC1, COMT, NRG1, DTNBP1, and BDNF act as genetic risk factors across schizoaffective disorder, and F25.9 cases are also expected to carry this polygenic risk load. The confirmation of high genetic correlation among schizophrenia, bipolar disorder, and major depressive disorder in large GWAS studies suggests that shared genetic risk exists wherever one lies on this spectrum.
Clinical importance of taking family history: Even at the F25.9 stage, a detailed history of schizophrenia, bipolar disorder, major depressive disorder, and suicide in the family provides important clues for future subtype classification and prognosis prediction. A family history of manic-type schizoaffective disorder suggests the possibility of reclassification to F25.0, and a family history of the depressive type suggests reclassification to F25.1.
Limits and principles of genetic counseling: Genetic counseling at the F25.9 stage is based on the risk for schizoaffective disorder in general (about 5–10% risk of onset in first-degree relatives), and differences in risk by subtype are updated after the subtype is established. The core of genetic counseling is to explain the polygenic nature of schizoaffective disorder, the importance of gene-environment interaction, and that clinical phenotypes can differ greatly even among individuals with the same genetic loading.
There are almost no independent epidemiologic data on schizoaffective disorder, unspecified (F25.9). This is because F25.9, as a provisional diagnostic code, is rarely retained as the final diagnostic code.
Use pattern as an administrative code: In health insurance claims data, the F25.9 code is used at a relatively high frequency at first visits, emergency presentations, and initial outpatient visits. When follow-up is subsequently carried out, a substantial proportion of patients are reclassified to a typical subtype (F25.0–F25.2) or another psychiatric diagnosis (schizophrenia F20, bipolar disorder F31, psychotic depression F32.3).
Characteristics as a provisional diagnosis: In clinical studies, the diagnostic stability of an F25.9 diagnosis within 3–5 years is low, with the diagnosis changing in about 40–60% of patients during follow-up. This confirms that F25.9 is a provisional state reflecting uncertainty in the diagnostic process.
Age and sex distribution: Considering cases in which F25.9 is applied in emergencies, the distribution is presumed to be relatively similar to the typical age at onset of schizoaffective disorder (15–30 years). However, F25.9 is also applied to atypical cases in the elderly or adolescents, so the age distribution is somewhat wider.
Current use in Korea: In Health Insurance Review & Assessment Service (HIRA) data of Korea, F25.9 accounts for a certain proportion of all F25 code use, reflecting uncertainty in initial diagnosis. Registration under Special Copayment Reduction V161 is possible with the F25.9 code, and the code can be changed once the subtype is established.
The pathophysiology of schizoaffective disorder, unspecified (F25.9), is understood as all the neurobiological mechanisms of schizoaffective disorder in general being potentially involved, since the subtype has not been determined. Once the subtype is established during the clinical course, the main mechanisms of that subtype can be understood to predominate.
Common neurobiological mechanisms: Mesolimbic dopamine hyperactivity (positive symptoms), prefrontal dopamine hypofunction (negative symptoms, cognitive impairment), serotonin system abnormality (mood symptoms), glutamate NMDA receptor hypofunction (negative and cognitive symptoms), and HPA axis hyperactivation (stress response) act in common in F25.9 cases as well.
Neural circuit abnormalities: Abnormal connectivity of the prefrontal-limbic-striatal circuit appears across various symptom domains. Dysfunction of the default mode network and salience network is associated with delusion formation and mood dysregulation. On structural MRI, lateral ventricular enlargement and gray matter reduction in the prefrontal and temporal lobes may be observed.
Provisional nature of pathophysiologic assessment: At the F25.9 stage, which neurobiological mechanism predominates is clinically estimated based on the main symptom type (positive psychotic symptoms, mania, depression) and reflected in drug selection. For example, a dopamine D2 blocker is chosen first when positive symptoms are prominent, and a mood stabilizer is chosen first when mood stabilization is the main goal. Once the subtype is established, treatment strategy is switched to one that fits the neurobiological mechanisms of that subtype.
In schizoaffective disorder, unspecified (F25.9), coexistence of schizophrenia symptoms and mood episodes is clinically confirmed, but the currently available information is insufficient to determine a specific subtype.
Psychotic symptoms identified: Auditory hallucinations, delusions, disorganized thinking and speech, and negative symptoms (affective blunting, avolition, alogia, social withdrawal) may appear. The presence of these symptoms supports classification as a schizophrenia spectrum disorder, but the characteristics of the mood episodes needed to determine the subtype have not been sufficiently assessed.
Mood symptoms identified: Elevated mood, grandiosity, decreased sleep, and flight of ideas (manic domain) or depressed mood, anhedonia, sleep disturbance, and suicidal ideation (depressive domain) may appear, but their duration, severity, and functional impact have not been sufficiently assessed, or it is difficult to determine whether it is mania, depression, or a mixed state.
Causes of insufficient information: Reasons for incomplete symptom assessment include patient noncooperation (acute agitation, severe psychomotor agitation, refusal of verbal communication), assessment during substance intoxication, language barriers, medical emergencies (accompanied by physical injury), and absence of a history provider. In these situations, securing a safe environment and immediate symptom control take priority.
Immediate assessment of suicide risk: Even in an F25.9 state with an undetermined subtype, immediate assessment of suicide risk must be carried out. Since the coexistence of psychotic symptoms and mood episodes itself raises suicide risk, within the scope of what can be assessed, confirm suicidal ideation, plans, and past attempts and take appropriate safety measures.
The clinical signs of schizoaffective disorder, unspecified (F25.9), are those seen in F25.0–F25.2 mixed together, or observed partially when sufficient assessment has not been done.
Psychiatric interview findings: One or both of the following are observed: behavior responding to auditory hallucinations (laughing or talking to oneself in response to internal stimuli, staring in a particular direction), delusional thought content (persecutory, grandiose, guilt), disorganized speech (loosening of associations, derailment), and pressured speech or decreased speech. The mood state may be one of elevated, depressed, mixed, or unassessable. Insight is often severely impaired.
Physical examination findings: In the acute state, tachycardia, blood pressure fluctuation, sweating, and signs of fatigue from sleep deprivation may appear. Physical examination to exclude organic causes (thyroid, neurologic examination, autoimmune signs) is especially important. Check for signs suggesting substance intoxication (pupillary abnormalities, sweating, shaking, tremor).
Limited application of assessment scales: Even when the subtype is undetermined, the PANSS, YMRS, and MADRS are administered whenever possible to collect baseline clinical data. This becomes important reference data for future subtype classification and tracking of treatment response. The C-SSRS (Columbia Suicide Severity Rating Scale) should be administered immediately in all states.
Establishing a longitudinal reassessment plan: At the initial evaluation, establish a plan for collecting additional information to determine the subtype. Scheduling interviews with family and caregivers, requesting records from previous medical institutions, and setting a follow-up schedule should be done as part of the initial evaluation.
At the stage of schizoaffective disorder, unspecified (F25.9), collecting additional information for reclassification to a typical subtype and thorough exclusion of organic causes are the key tasks.
Tests to exclude organic causes: Perform the same comprehensive tests to exclude organic causes as for F25.0–F25.2. Includes blood tests (CBC, electrolytes, liver function, kidney function, thyroid function [TSH, FT4], vitamin B12, folate, blood glucose, CRP, RPR, HIV), urine toxicology (comprehensive drug screening), brain MRI (or CT in emergencies), and EEG when needed. When autoimmune encephalitis is suspected, anti-NMDAR, anti-LGI1, and anti-CASPR2 antibodies and CSF analysis are added.
Collecting additional information for subtype classification: When the patient becomes able to cooperate, perform a structured clinical interview (SCID-5, MINI) to assess the characteristics of mood episodes. Obtain from family or caregivers the history of past mood episodes, changes in sleep patterns, and behavioral changes. Review records from previous medical institutions (psychiatric outpatient, inpatient, and emergency visits) to confirm previous diagnoses and treatment responses.
Suicide risk assessment and safety planning: Immediate suicide risk assessment is essential even when the subtype is undetermined. Perform the C-SSRS whenever possible, and if suicide risk is high, immediate inpatient treatment and safety measures are needed.
Schizoaffective disorder, unspecified (F25.9) is a provisional diagnostic code used when, owing to a lack of sufficient clinical information, the case cannot be classified into a typical subtype (F25.0–F25.2) or other (F25.8).
Conditions for applying F25.9: Applied when coexistence of schizophrenia symptoms and mood episodes is clinically confirmed so that the case belongs to the schizoaffective disorder category, but with currently available information it cannot be definitively classified into any of F25.0 (manic type), F25.1 (depressive type), F25.2 (mixed type), or F25.8 (other). Representative situations include emergency first visits, inability to take a history, a stage before substance use has been excluded, and situations where assessment of mood episode characteristics is incomplete.
Distinction from F25.8: F25.8 (other) is used when there is sufficient information but the case does not meet the criteria of a typical subtype, whereas F25.9 (unspecified) is used when the information itself is insufficient, which distinguishes them conceptually. However, in clinical practice this distinction is not always clear.
Importance of differential diagnosis: Even at the F25.9 stage, it should be recorded that differentiation is in progress from organic psychosis (F06.0–F06.2), substance-induced psychosis (F1x.5), bipolar disorder with psychotic features (F31.2, F31.5), schizophrenia (F20), and psychotic depression (F32.3). As the results of differential diagnosis are sorted out, reclassification to a more specific code than F25.9 takes place.
Recommended time limit for use of a provisional diagnosis: Clinically, the aim is to reclassify the F25.9 code to a typical subtype or another diagnosis within 6–12 months where possible. When it is maintained as F25.9 for a long time, diagnostic reassessment is needed.
In schizoaffective disorder, unspecified (F25.9), treatment based on the main symptom type must be started immediately even when the subtype is undetermined. Delay in treatment can worsen prognosis, so symptom-based treatment proceeds without waiting for full diagnostic establishment.
Symptom-based initial treatment: If positive psychotic symptoms (auditory hallucinations, delusions, disorganized thinking) are the main clinical problem, second-generation antipsychotics (olanzapine, risperidone, paliperidone, quetiapine, aripiprazole) are the first choice. A short-term benzodiazepine (lorazepam) can be added for severe agitation and excitement. If an acute manic picture is prominent, a mood stabilizer (valproate) is added to the antipsychotic early. If a depressive picture is clear, consider starting an SSRI or SNRI in combination with the antipsychotic.
Early consideration of mood stabilizers: Even at the F25.9 stage, if there is a possibility of a mood episode (manic or depressive), it is safe to add a mood stabilizer early. Valproate is effective for both manic and mixed pictures, and quetiapine has both antipsychotic and antidepressant effects, making it useful in situations where the subtype is undetermined.
Switching treatment after subtype is established: When the subtype is established as F25.0 (manic type), switch to maintenance therapy with lithium or valproate + antipsychotic combination. When established as F25.1 (depressive type), consider adding an antidepressant. When established as F25.2 (mixed type), apply combination drug therapy (consider including clozapine).
Psychosocial intervention: Even when the subtype is undetermined, basic psychological support, education of the patient and family (including the uncertainty of the illness), and establishment of a safety plan should be provided. Structured psychosocial treatment is started after acute-phase stabilization.
The prognosis of schizoaffective disorder, unspecified (F25.9), generally follows the prognostic characteristics of schizoaffective disorder in general, since the subtype has not been determined. Once the subtype is established, the prognostic characteristics of that subtype apply.
Diagnostic stability and prognosis: Because F25.9 is a provisional diagnostic code, the diagnosis is not yet stabilized. According to research, the rate of diagnostic change within 3–5 years in patients with an initial F25.9 (schizoaffective disorder NOS) diagnosis reaches about 40–60%. If the final diagnosis changes to bipolar I disorder, a prognosis comparable to manic-type schizoaffective disorder (relatively good) can be expected, and if it changes to schizophrenia, a poorer long-term prognosis may be seen.
Importance of early diagnostic establishment: The longer the F25.9 state is prolonged, the harder it is to establish an appropriate treatment strategy, and the more uncertain the prediction of treatment response becomes. The earlier the diagnosis is established as a typical subtype, the more evidence-based treatment protocols can be applied to improve prognosis.
Common factors affecting prognosis: Delayed treatment, substance abuse, poor treatment adherence, and lack of social support are factors worsening prognosis, and these should be managed at the F25.9 stage regardless of subtype. Early start of drug treatment, family psychoeducation, and linkage with community mental health services contribute to improved prognosis at the F25.9 stage as well.
Prevention of schizoaffective disorder, unspecified (F25.9), is based on the prevention principles of schizoaffective disorder in general, and after the subtype is established, it switches to the subtype-specific prevention plan.
Immediate relapse prevention plan: Establish a relapse prevention plan immediately after acute-phase stabilization. Educate the patient and family on the need for maintenance pharmacotherapy, methods of securing treatment adherence (including LAI), and how to recognize relapse prodromal symptoms. Establish a suicide prevention safety plan and provide contact numbers for crisis situations.
Switching the prevention plan after subtype is established: The prevention strategy is switched as follows: when the subtype is established as F25.0, long-term lithium maintenance (antisuicidal, antimanic); for F25.1, antidepressant maintenance and intensive suicide prevention management; for F25.2, maintenance of combination therapy including clozapine.
Substance abuse prevention and lifestyle management: All schizoaffective disorder patients are educated to completely avoid cannabis, alcohol, and stimulants. Maintaining a regular sleep rhythm, regular meals, exercise, and stress management help prevent episodes and maintain overall health. Smoking cessation and monitoring for metabolic disease are also important for maintaining long-term health.
Linkage with community mental health services: Plan linkage with community mental health welfare centers, day hospitals, day care programs, and the mental health crisis counseling hotline (1577-0199) from the beginning. Encourage participation in family psychoeducation programs and, when needed, consider home-visit intensive community treatment (ACT) services.
Malaspina D, Owen MJ, Heckers S, et al. Schizoaffective disorder in the DSM-5. Schizophr Res. 2013;150(1):21-25. DOI: 10.1016/j.schres.2013.04.026. PMID: 23707642.
Heckers S, Barch DM, Bustillo J, et al. Structure of the psychotic disorders classification in DSM-5. Schizophr Res. 2013;150(1):11-14. DOI: 10.1016/j.schres.2013.04.039. PMID: 23707641.
Cheniaux E, Landeira-Fernandez J, Telles LL, et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord. 2008;106(3):209-217. DOI: 10.1016/j.jad.2007.07.009. PMID: 17825415.
Murru A, Pacchiarotti I, Nivoli AM, et al. What we know and what we don't know about the treatment of schizoaffective disorder. Eur Neuropsychopharmacol. 2011;21(9):680-690. DOI: 10.1016/j.euroneuro.2011.03.010. PMID: 21482081.
Jäger M, Becker T, Weinmann S, Frasch K. Treatment of schizoaffective disorder — a challenge for evidence-based psychiatry. Acta Psychiatr Scand. 2010;121(1):22-32. DOI: 10.1111/j.1600-0447.2009.01424.x. PMID: 19522882.
Pagel T, Baldessarini RJ, Franklin J, Baethge C. Characteristics of patients diagnosed with schizoaffective disorder compared with schizophrenia and bipolar disorder. Bipolar Disord. 2013;15(3):229-239. DOI: 10.1111/bdi.12057. PMID: 23528001.
Cascade EF, Kalali AH, Buckley P. Treatment of schizoaffective disorder. Psychiatry (Edgmont). 2009;6(3):15-17. PMID: 19724741.
Kendler KS, McGuire M, Gruenberg AM, Walsh D. Examining the validity of DSM-III-R schizoaffective disorder and its putative subtypes in the Roscommon Family Study. Am J Psychiatry. 1995;152(5):755-764. DOI: 10.1176/ajp.152.5.755. PMID: 7726313.
Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders. J Clin Psychiatry. 2007;68(6):899-907. DOI: 10.4088/jcp.v68n0612. PMID: 17592915.
Harrow M, Grossman LS, Herbener ES, Davies EW. Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br J Psychiatry. 2000;177:421-426. DOI: 10.1192/bjp.177.5.421. PMID: 11059995.